Leishmania infection in patients with inflammatory bowel disease: Case series and literature review

Gastroenterol Hepatol. 2024 Jan;47(1):82-92. doi: 10.1016/j.gastrohep.2023.04.001. Epub 2023 Apr 13.
[Article in English, Spanish]

Abstract

Infection by Leishmania spp. in patients diagnosed with inflammatory bowel disease (IBD) is rare. Considered endemic in the Mediterranean basin, its manifestations are almost exclusive of patients with impaired cellular immunity. Most of the evidence is found through case reports; without guidelines for its management in patients with IBD. In this study we present three cases of Leishmania infection in patients with IBD that lead us to carry out a review of the current literature. Immunosuppressive treatment contributes to this infection, which presents atypically, with a challenging diagnosis. Initial systemic treatment with withdrawal of the immunosuppressant drug seems to be the best therapeutic strategy. Studies are needed in endemic areas to determine its incidence in IBD patients, as well as its possible association with immunosuppressive therapy. The need for serological screening prior introduction of immunosuppressive drugs could be suggested.

Keywords: Colitis ulcerosa; Crohn's disease; Enfermedad de Crohn; Enfermedad inflamatoria intestinal; Inflammatory bowel disease; Leishmaniasis; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Inflammatory Bowel Diseases* / complications
  • Inflammatory Bowel Diseases* / drug therapy
  • Inflammatory Bowel Diseases* / epidemiology
  • Leishmaniasis* / complications
  • Leishmaniasis* / drug therapy

Substances

  • Immunosuppressive Agents